Contact Us

If you have a question about a medical condition, consult with a healthcare professional or, in the case of an emergency, call 911 immediately.

Standard business hours for CSL Behring are 8:30 am to 5:00 pm Eastern time.

CSL Behring Headquarters

Phone: 610-878-4000
Fax: 610-878-4009
Location: North America Headquarters
Address: P.O. Box 61501
1020 First Avenue
King of Prussia, PA 19406 USA

Consumer Affairs

For Consumer Information
Phone: 888-508-6978
Fax: 610-878-4008

Medical Affairs

Phone: 800-504-5434
Fax: 610-878-4007

Adverse Events

To Report an Adverse Event
US Pharmacovigilance
1-866-915-6958
(available 24 hrs/day)

All fields marked with an asterisk (*) are required.

To ensure that your question or comment is directed to the appropriate CSL Behring department, please select one of these choices:*

Salutation:*
First Name:*
Last Name:*

I am a:*

E-mail Address:*
Confirm E-mail Address:*
Phone Number:*

Please enter your comments:

Type in the verification word in the box below and click "Submit."

Submit Reset

Prior to submitting your information, please review our Privacy Policy.

Important Safety Information

Alpha₁-Proteinase Inhibitor (Human), Zemaira^® is indicated to raise the plasma level of alpha₁-proteinase inhibitor (A₁-PI) in patients with A₁-PI deficiency and related emphysema. The effect of this raised level on the frequency of pulmonary exacerbations and the progression of emphysema have not been established in clinical trials.

Zemaira may not be suitable for everyone; for example, people with known hypersensitivity to components used to make Zemaira, those with a history of anaphylaxis or severe systemic response to A₁-PI products, and those with certain IgA deficiencies. If you think any of these may apply to you, ask your doctor.

Early signs of hypersensitivity reactions to Zemaira include hives, rash, tightness of the chest, unusual breathing difficulty, wheezing, and feeling faint. Immediately discontinue use and consult with physician if such symptoms occur.

In clinical studies, the following adverse reactions were reported in at least 5% of subjects receiving Zemaira: headache, sinusitis, upper respiratory infection, bronchitis, fatigue, increased cough, fever, injection-site bleeding, nasal symptoms, sore throat, and swelled blood vessels.

Because Zemaira is made from human blood, the risk of transmitting infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Please see full prescribing information for Zemaira.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.